Enhancing T cell immunotherapies with synthetic signalling receptors
Cellular immunotherapies against cancer have made great progress in recent years using engineered T-cells with synthetic protein receptors called chimeric antigen receptors (CARs). Researchers from Sai Reddy’s lab and colleagues at the University Hospital Basel now present a technology platform to speed up the discovery of CAR variants with enhanced tumour killing properties and use the genetic construction plan for engineering next-generation CAR T cells.
Find original publication in Nature Communications:
Castellanos-Rueda, R, RB Di Roberto, F Bieberich, FS Schlatter, D Palianina, OTP Nguyen, E Kapetanovic, H Läubli, A Hierlemann, N Khanna and ST Reddy (2022) external page SpeedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing. Nat Commun 13, 6555. https://doi.org/10.1038/s41467-022-34141-8
Learn about the Systems and Synthetic Immunology Lab led by Sai Reddy.